Cargando…
Emerging treatment options for management of malignant ascites in patients with ovarian cancer
Malignant ascites affects approximately 10% of patients with recurrent epithelial ovarian cancer and is associated with troublesome symptoms, including abdominal pressure and distension, dyspnea, bloating, pelvic pain, and bowel/bladder dysfunction. To date, no effective therapy has been identified...
Autores principales: | Eskander, Ramez N, Tewari, Krishnansu S |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3422105/ https://www.ncbi.nlm.nih.gov/pubmed/22927770 http://dx.doi.org/10.2147/IJWH.S29467 |
Ejemplares similares
-
Epithelial cell-adhesion molecule-directed trifunctional antibody immunotherapy for symptom management of advanced ovarian cancer
por: Eskander, Ramez N, et al.
Publicado: (2013) -
Beyond angiogenesis blockade: targeted therapy for advanced cervical cancer
por: Eskander, Ramez N., et al.
Publicado: (2014) -
Fifth annual workshop of cytoreductive surgery for advanced ovarian cancer and peritoneal surface malignancies
por: Tewari, Krishnansu S.
Publicado: (2016) -
Bevacizumab in the treatment of ovarian cancer
por: Eskander, Ramez N, et al.
Publicado: (2011) -
Targeted treatment of advanced ovarian cancer: spotlight on rucaparib
por: Pearre, Diana C, et al.
Publicado: (2018)